Navigation Links
Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
Date:9/25/2008

potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that predict individual patient response to Gencaro. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.

Forward-looking statements

This press release contains "forward-looking statements" which include, without limitation, statements regarding the completion of the proposed merger transaction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transaction's anticipated benefits, timing, progress and anticipated completion of the combined company's clinical stage and research programs, including possible regulatory approval, the potential benefits that patients may experience from the use of the combined company's clinical stage compounds, and the cash position of the combined company, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securitie
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
4. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
5. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
6. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
7. China Biopharma Effects 1 for 100 Reverse Stock Split
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. Therapure Biopharma Inc. opens for business with first client contracts
10. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Quorum Review IRB, the industry ... large clinical trials called Quick Step™ . The offering ... address the research industry’s need for seamless study start-up with ... available for studies planning 50 or more North American investigator ... North American site count of 80 or more. Qualifying studies ...
(Date:7/22/2014)... Jersey , 22. Juli 2014 ... Life-Sciences-Industrie, hat die Ernennung von Marcus Bergler zum ... Herr Bergler hat die europäischen kommerziellen Aktivitäten von ... Bevor er sich Qforma anschloss, war er in ... Customer Information, als Vertriebsteam-Leiter Deutschland bei IMS Health ...
(Date:7/22/2014)... Greenville, SC (PRWEB) July 22, 2014 ... chorus of those who have recognized that the greatest ... inefficient, and far too often needlessly deadly while trying ... the multitude of quasi-experts seeking to transform an enormous ... detail.” , Dr. Williams, in his continuing series of ...
(Date:7/21/2014)... amount of tension to a chain of carbon atoms ... insulator, according to Rice University scientists. , Stretching the ... of carbon atoms -- by just 3 percent can ... might find useful for mechanically activated nanoscale electronics and ... Yakobson and his colleagues appears in the American Chemical ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2Carbyne morphs when stretched 2Carbyne morphs when stretched 3
... DIEGO, June 2 Amylin Pharmaceuticals,Inc. (Nasdaq: ... present new data,for its FDA-approved diabetes drugs, BYETTA(R) ... pipeline diabetes and,obesity drug candidates at the American ... in San Francisco, CA from June 6 to,10. ...
... Alternative Reproductive Resources,(ARR), a leading Chicago-based agency ... mothers, has announced a program designed,to remove some ... process., Called Extended Choice, the program offers ... selected egg donors during a 72-hour period.,This means ...
... The Scarborough Hospital (TSH),Canada,s largest urban community hospital, ... communications between physicians. The,implementation of Chyma(TM) for their ... the busy ER departments at the two hospital ... of general medicine., "Chyma(TM) reflects the commitment ...
Cached Biology Technology:Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 2Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 3Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 4Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 5Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 6Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008 7ARR Offers Parents 'Extended Choice' in Egg Donor Selections 2Canada's Largest Urban Community Hospital Chooses Chyma(TM) On-Call Physician Scheduling Technology 2
(Date:7/22/2014)... that drinking milk helps make their bones strong or that fish ... idea that if something is good for us, it must surely ... of Consumer Research , when children hear about the benefits of ... that when food is presented to children as making them strong ... how to read or count, they would conclude the food is ...
(Date:7/22/2014)... in schoolyards that feature natural habitats and trees and ... and inattention, according to a University of Colorado Boulder ... such settings also provide stress-reducing benefits for youth, according ... & Place. The study is one of the ... between student access to green settings and stress. , ...
(Date:7/22/2014)... July 22, 2014, Cleveland: A type of immune ... diseases, such as Alzheimer,s disease and multiple sclerosis ... brain injury (TBI) and may slow the progression ... published today in the online journal Nature ... Bruce Trapp, PhD, Chair of the Department of ...
Breaking Biology News(10 mins):Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 2Natural-terrain schoolyards reduce children's stress, says Colorado University-Boulder study 3Cleveland Clinic researchers discover neuroprotective role of immune cell 2
... Endeavour International Corporation (NYSE Amex: END ) (LSE: ENDV) will ... on Monday, May 17, 2010 in London .   , ... William L. Transier , chairman, chief ... and operational plans at 11:05 a.m. British Summer Time and ...
... DENVER , April 26 M.D.C. Holdings, Inc. (NYSE: MDC ... of twenty-five cents ($.25) per share on the Company,s common stock. ... record on Wednesday, May 12, 2010 . , ... M.D.C. Holdings, Inc. , , , ...
... LOS ANGELES , April 26 Northrop Grumman Corporation (NYSE: ... Virginia , concluding a search that also included the state of ... , , ... as the home for our new corporate office.  Virginia, Maryland and ...
Cached Biology News:M.D.C. Holdings Declares Quarterly Cash Dividend 2Northrop Grumman Selects Virginia for New Corporate Office 2Northrop Grumman Selects Virginia for New Corporate Office 3
... and supplies, for 10 chips, provides ... perform high-sensitivity RNA analysis (picogram levels) ... automated electrophoresis system. Supplied are 1,250 ... HighSens stain, 20 microliters RNA ladder, ...
... 3-(3,5-Dibromo-4-hydroxy-benzoyl)-2-ethyl-benzofuran-6-sulfonicacid-(4-(thiazol-2-ylsulfamyl)-phenyl)-amide White solid. PROTECT ... A cell-permeable sulfanamido-benzbromarone compound that acts ... allosteric inhibitor of PTP1B (IC 50 ... μM for PTP1B 403 and ...
...
... White walled plates enhance luminescent signals ... fluorescence,• Not treated (or medium binding) ... and binds biomolecules through passive interactions,• ... of large molecules, such as antibodies, ...
Biology Products: